A Web-Based Dynamic Nomogram to Predict the Risk of Methicillin-Resistant Staphylococcal Infection in Patients with

Van Duong-Thi-Thanh1,2, Binh Truong-Quang1,3, Phu Tran-Nguyen-Trong2,4

  • 1Faculty of Medicine, University of Medicine and Pharmacy, Ho Chi Minh 700000, Vietnam.

PubMed

Insights

This study developed a web tool to predict methicillin-resistant Staphylococcus spp. (MRS) infection risk in pneumonia patients. Key predictors include tracheostomies and skin infections, guiding empiric antibiotic therapy decisions.

Area of Science:

  • Infectious Diseases
  • Medical Informatics
  • Clinical Prediction Modeling

Background:

  • Pneumonia poses significant risks, with methicillin-resistant Staphylococcus spp. (MRS) presenting a growing challenge.
  • Accurate prediction of MRS infection is crucial for timely and appropriate patient management.

Purpose of the Study:

  • To develop a dynamic, web-based tool for predicting MRS infection risk in pneumonia patients.
  • To identify key clinical predictors associated with MRS infection in this population.

Main Methods:

  • An observational study was conducted with pneumonia patients over two years.
  • Bayesian model averaging and stepwise selection identified independent predictors.
  • The model was validated using bootstrap resampling and assessed with ROC, calibration, and decision curve analyses.

Main Results:

  • A predictive model was developed, identifying tracheostomies/endotracheal tubes, skin infections, pleural effusions, and pneumatoceles as significant risk factors.
  • The model achieved an Area Under the Curve (AUC) of 0.70 (0.63-0.77) in the dataset and 0.71 (0.64-0.78) in bootstrap samples.
  • An optimal cut-off of 0.3 was determined, with a recommended threshold for empiric antibiotic therapy.

Conclusions:

  • The developed nomogram model effectively predicts MRS infection risk in pneumonia patients.
  • The web-based tool provides a user-friendly interface for clinical application.
  • Empiric antibiotic therapy is recommended for patients with a predicted risk above 0.3.